Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00809302
Recruitment Status : Terminated (Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.)
First Posted : December 17, 2008
Last Update Posted : August 28, 2009
Information provided by:
Neurogen Corporation

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Estimated Primary Completion Date : August 2009
  Estimated Study Completion Date : October 2009